Lupin Limited announced the appointment of Spiro Gavaris as President U.S. Generics business. As part of Lupin's senior leadership team, Spiro will be responsible for the overall strategy, implementation and growth of Lupin's U.S. Generics business. Spiro joins Lupin with significant experience in the branded, generic and biotech industries. He most recently served as President of Specialty Generics business at Mallinckrodt Pharmaceuticals and the
President of US Injectables at Hikma.